

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

XTL BIOPHARMACEUTICALS LTD  
Form SC 13D/A  
December 03, 2008

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

SCHEDULE 13D/A

(RULE 13D-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(a) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(a)(1)

XTL BIOPHARMACEUTICALS LTD.

-----  
(Name of Issuer)

AMERICAN DEPOSITORY RECEIPTS,  
EACH REPRESENTING TEN ORDINARY SHARES, PAR VALUE NIS 0.02

-----  
(TITLE OF CLASS OF SECURITIES)

98386D109

-----  
(CUSIP NUMBER)

JOSEPH EDELMAN, 499 PARK AVENUE, 25TH FLOOR, NEW YORK, NY 10022, (646) 205-5300

-----  
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED  
TO RECEIVE NOTICE AND COMMUNICATIONS)

NOVEMBER 18, 2008

-----  
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D/A, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. SEE Rule 13d-7(b) for other parties to whom copies are to be sent.

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

CUSIP No. 98386D109

13D/A

Page 2

1.

NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

PERCEPTIVE ADVISORS LLC

2.

CHECK THE APPROPRIATE BOX IF A GROUP\*  
(a)

(b)

3.

SEC USE ONLY

4.

SOURCES OF FUNDS

OO (Funds from Investment Advisory Clients).

5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

6.

CITIZENSHIP OR PLACE OF ORGANIZATION  
DELAWARE

NUMBER OF  
SHARES

7.

SOLE VOTING POWER

BENEFICIALLY  
OWNED BY

8.

SHARED VOTING POWER 510,000

EACH  
REPORTING

9.

SOLE DISPOSITIVE POWER

PERSON WITH

10.

SHARED DISPOSITIVE POWER 510,000

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 510,000

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES \*

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

0.17%

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

14.

TYPE OF REPORTING PERSON\*  
IA

\*SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 98386D109

13D/A

Page 3

1.

NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

JOSEPH EDELMAN

2.

CHECK THE APPROPRIATE BOX IF A GROUP\*

3.

SEC USE ONLY

4.

SOURCES OF FUNDS

OO

5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

UNITED STATES OF AMERICA

NUMBER OF  
SHARES

7.

SOLE VOTING POWER

0

BENEFICIALLY  
OWNED BY

8.

SHARED VOTING POWER

510,000

EACH  
REPORTING

9.

SOLE DISPOSITIVE POWER

0

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

PERSON WITH 10. SHARED DISPOSITIVE POWER 510,000

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 510,000

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES \*

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 0.17%

14. TYPE OF REPORTING PERSON\*  
IN

\* SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No. 98386D109

13D/A

Page 4 of 7 Pages

ITEM 1 SECURITY AND ISSUER

This Schedule 13D/A relates to the ordinary shares, par value NIS 0.02 (the "Ordinary Shares") (represented by ownership of American Depository Receipts), of XTL Biopharmaceuticals Ltd. (the "Issuer"). The address of the principal executive offices of the Issuer is 711 Executive Blvd., Suite Q, Valley Cottage, NY 10989.

ITEM 2 IDENTITY AND BACKGROUND

(a) The names of the persons filing this Schedule 13D/A (the "Schedule") are Perceptive Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Joseph Edelman, the Managing Member of the Investment Manager. Such reporting persons are collectively referred to herein as the "Reporting Persons."

The Investment Manager, in its capacity as investment manager of Perceptive Life Sciences Master Fund Ltd., a Cayman Islands company (the "Fund"), and to an account of First New York Trading, LLC (the "FNY Account"), has sole power to vote and dispose of the Ordinary Shares held by the Fund and the FNY Account. The Investment Manager disclaims any economic interest in or beneficial ownership of the Ordinary Shares covered by this Schedule.

(b) The business address of the Reporting Persons is 499 Park Avenue, 25th Floor, New York, NY 10022.

(c) This Schedule is filed on behalf of the Investment Manager, Mr. Edelman, the Fund and the FNY Account. The Fund and FNY Account are the record and direct beneficial owners of the Ordinary Shares reported herein. The Investment Manager is the investment manager to the Fund and the FNY Account. Mr. Edelman is the Managing Member of the Investment Manager. The principal business of the Investment Manager is purchasing, holding and selling securities for investment purposes. The principal business of each of the Fund and the FNY

## Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

Account is to invest in securities.

(d) During the past five years none of the Reporting Persons has been convicted in a criminal proceeding.

(e) During the past five years none of the Reporting Persons has been a party to a civil proceeding as a result of which it is subject to a judgment, decree or final order enjoining it from or mandating activities subject to federal or state securities laws, or finding it in violation of such laws.

(f) Perceptive Advisors LLC is organized under the laws of Delaware, USA. Mr. Edelman is a citizen of the United States of America.

### ITEM 3 SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The Fund and the FNY Account sold the Ordinary Shares in open market transactions.

CUSIP No. 98386D109

13D/A

Page 5 of 7 Pages

### ITEM 4 PURPOSE OF TRANSACTION

The Reporting Persons sold the Ordinary Shares of the Issuer in the ordinary course of business.

The Reporting Persons expect to acquire or dispose of additional Ordinary Shares via open-market transactions from time to time. However, there is no timetable or pre-arranged plan related to the purchase or sale of additional Ordinary Shares. Such decisions will be made based on trading activity and the relative value of the Ordinary Shares, as defined by market conditions.

### ITEM 5 INTEREST IN SECURITIES OF THE ISSUER

(a)-(b) The Reporting Persons may be deemed, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, to be the beneficial owners of an aggregate of 510,000 Ordinary Shares as of November 21, 2008, which represent 0.17% of the Issuer's outstanding Ordinary Shares. Mr. Edelman beneficially owns 510,000 Ordinary Shares (comprised of 510,000 Ordinary Shares held by the Fund).

The percentage calculation was based on the number of Ordinary Shares the Issuer reported as outstanding on its Form S-8 as filed with the Commission on October 28, 2008. The amount of outstanding Ordinary Shares reported on such Form was 292,805,326 as of June 30, 2008.

	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power
Perceptive Advisors LLC	0	510,000	0	510,000
Joseph Edelman	0	510,000	0	510,000

The aggregate amount of shares owned by the Reporting Persons is 510,000.

## Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

(c) Except as set forth below, there have been no transactions in the Ordinary Shares by any of the Reporting Persons during the past sixty days.

CUSIP No. 98386D109

13D/A

Page 6 of 7 Pages

During the past sixty days, the Reporting Persons effected the following sales of Ordinary Shares in open market transactions:

DATE	SHARES SOLD	PRICE
11/18/2008	2,974	0.159
11/18/2008	40,000	0.1614
11/18/2008	194,325	0.14095
11/18/2008	40,000	0.1528
11/18/2008	29,957	0.1528
11/18/2008	2,468,136	0.140936
11/18/2008	269,645	0.15285
11/19/2008	960,000	0.15280
11/19/2008	71,100	0.1489
11/19/2008	50,000	0.1551
11/21/2008	960,000	0.14890
11/21/2008	925,926	0.1526

(d) Not applicable.

(e) The Reporting Persons ceased to be beneficial owners of more than five percent of the Ordinary Shares on November 21, 2008.

ITEM 6 CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

None.

ITEM 7 MATERIAL TO BE FILED AS EXHIBITS

Joint Filing Agreement, dated as of December 3, 2008, by and among Perceptive Advisors LLC and Joseph Edelman.

CUSIP No. 98386D109

13D/A

Page 7 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

December 3, 2008

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

Date

/s/ Perceptive Advisors LLC  
Signature

Joseph Edelman/Managing Member  
Name/Title

December 3, 2008  
Date

/s/ Joseph Edelman  
Signature

Joseph Edelman  
Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. SEE ss.240.13d-7 for other parties for whom copies are to be sent.

INDEX TO EXHIBITS

Exhibit 1                    Joint Filing Agreement, dated as of December 3, 2008, by and among Perceptive Advisors LLC and Joseph Edelman.

EXHIBIT 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D/A (including amendments thereto) with regard to the Ordinary Shares of XTL Biopharmaceuticals Ltd., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Agreement as of December 3, 2008.

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form SC 13D/A

December 3, 2008  
Date

/s/ Perceptive Advisors LLC  
Signature

Joseph Edelman/Managing Member  
Name/Title

December 3, 2008  
Date

/s/ Joseph Edelman  
Signature

Joseph Edelman  
Name/Title